Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...

Jefferies analyst Akash Tewari maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target ...

Madrigal (MDGL) delivered earnings and revenue surprises of 29.11% and 86.15%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Q3 2024 Earnings Call Transcript October 31, 2024 Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Madrigal Pharmaceuticals' Rezdiffra for NASH shows strong early demand, positioning the company as a market leader. Read why ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given a consensus rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the stock, Marketbeat ...

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports ...

WEST CONSHOHOCKEN, Pa. (AP) — WEST CONSHOHOCKEN, Pa. (AP) — Madrigal Pharmaceuticals Inc. (MDGL) on Thursday reported a loss of $107 million in its third quarter. On a per-share basis, the West ...

Sibold credited Rezdiffra's sales growth to the growing adoption of the treatment by prescribers, broader payer coverage for ...

Analysts expect Madrigal Pharmaceuticals to report an earnings per share (EPS) of $-7.09. The announcement from Madrigal Pharmaceuticals is eagerly anticipated, with investors seeking news of ...